Open AccessFolic Acid Therapy and Cardiovascular Disease in ESRD or Advanced Chronic Kidney Disease
Author(s) -
Xianhui Qin,
Yong Huo,
Craig B. Langman,
Fan Fan Hou,
Yundai Chen,
Debora Matossian,
Xiping Xu,
Xiaobin Wang
Publication year - 2010
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.05310610
Subject(s) - medicine , homocysteine , relative risk , kidney disease , folic acid , clinical trial , randomized controlled trial , gastroenterology , surgery , confidence interval
The efficacy of folic acid therapy to lower homocysteine (Hcy) levels in an effort to reduce cardiovascular disease (CVD) risk in patients with ESRD or advanced chronic kidney disease (ACKD; creatinine clearance, <30 ml/min) remains inconclusive. We conducted a meta-analysis of relevant randomized trials to further examine this issue.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom